Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents
- 1 January 1983
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 24 (6) , 797-799
- https://doi.org/10.1007/bf00607090
Abstract
The oxidative metabolism of bufuralol is under the same genetic control as that of debrisoquine and sparteine. 154 fasting volunteers received a 30 mg tablet of bufuralol and a blood sample was taken 3 h later. In poor metabolizers (8% of the sample) the plasma bufuralol concentrations were very high and the metabolite concentrations were low. The genetic oxidative status is a major source of interindividual variation in the plasma concentration of drugs that undergo oxidative metabolism.Keywords
This publication has 25 references indexed in Scilit:
- HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATIONThe Lancet, 1982
- BETA-BLOCKERS AND DRUG OXIDATION STATUSThe Lancet, 1982
- Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.BMJ, 1982
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- GENETICALLY DETERMINED IMPAIRED DRUG SULPHOXIDATIONThe Lancet, 1981
- GENETIC IMPAIRMENT OF PHENFORMIN METABOLISMThe Lancet, 1980
- Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamineXenobiotica, 1979
- Polymorphism of carbon oxidation of drugs and clinical implications.BMJ, 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- The metabolism of bufuralol: Urinary metabolite profiles in rat, dog and manEuropean Journal of Drug Metabolism and Pharmacokinetics, 1976